NDAINTRAVENOUSSOLUTION
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
KYXATA (carboplatin) by Viatris (2) is platinum-based drug that binds to dna and forms dna cross-links. First approved in 2025.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KYXATA is a platinum-based chemotherapy agent (carboplatin) approved in August 2025 as an intravenous solution for cancer treatment. It works by binding to DNA and forming cross-links that inhibit replication and transcription, triggering cytotoxic cell death. The product represents Viatris's entry into the established platinum-based oncology market.
Launch18.8 years to LOE
Early-stage launch with zero competitive pressure creates opportunity for rapid market penetration and team expansion, though long-term commercial potential depends on indication portfolio clarity.
Mechanism of Action
platinum-based drug that binds to DNA and forms DNA cross-links. These crosslinks inhibit DNA replication and transcription and trigger cytotoxic processes that lead to cell death.
Pharmacologic Class:
Platinum-based Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Started Dec 2030
0Salivary Gland CarcinomaAdenoid Cystic CarcinomaSalivary Gland Cancer+1 more
Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer
Started Jun 2027
16 enrolled
Lung Non-Squamous Non-Small Cell Carcinoma
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Started Jun 2026
390 enrolled
Extrapulmonary Neuroendocrine Cancer
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
Started Apr 2026
670 enrolled
Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer
Started Mar 2026
50 enrolled
Head &Amp; Neck CancerHead &Amp; Neck Squamous Cell Carcinoma
Worked on KYXATA at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.